Price Disclosure Reductions for 2021 April Cycle

Page last updated: 2 March 2021

This summary only includes medicines taking a price disclosure reduction on 1 April 2021. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2021 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Outcomes for flow-on price disclosure reductions to F2 combination items have been communicated to responsible persons with brands of affected drugs in January 2021.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2020 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2020 will also take the reduction on 1 April 2021 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process.

The date for lodgement of disputes was by 5:00pm AEDT on 8 January 2021.

Indicative prices for 1 April 2021(including price to pharmacy, dispensed price for maximum quantity and price premiums) was published on 20 January 2021.

Final prices for 1 April 2021 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2021.

Excel version of 2021 April Cycle Outcomes Summary

2021 April Cycle Outcomes Summary
Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)	Legal Instrument Manner of Administrtaion (MoA)	Legal Instrument Form	Average AEMP ($)	WAPD (%) across a drug/MoA	WADP - April '21 PBS Price (AEMP) ($) per pharmaceutical item	October '20 AEMP ($)	Percentage difference between October '20 and April '21 PBS prices (AEMP) (%) per pharmaceutical item	Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item	Applicable Unadjusted Price Reduction 10% or 30%
			[Average AEMP minus WAPD = WADP]			[Difference between October '20 AEMP & WADP = % Difference]
Anastrozole	Tablet 1 mg	Oral	16.78	31.88	11.43	16.78	31.88%	GWAPD	30
Aripiprazole	Tablet 10 mg	Oral	64.54	22.11	50.27	57.33	12.31%	GWAPD	10
Aripiprazole	Tablet 15 mg	Oral	91.59	22.11	71.34	81.35	12.30%	GWAPD	10
Aripiprazole	Tablet 20 mg	Oral	111.49	22.11	86.84	99.03	12.31%	GWAPD	10
Aripiprazole	Tablet 30 mg	Oral	135.86	22.11	105.82	120.67	12.31%	GWAPD	10
Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	474.81	12.83	413.89	474.81	12.83%	OWAPD	10
Bosentan	Tablet 125 mg (as monohydrate)	Oral	1113.08	44.96	612.64	898.26	31.80%	GWAPD	10
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	1113.08	44.96	612.64	898.26	31.80%	GWAPD	10
Cefuroxime*	Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL	Oral	8.00	15.13	6.79	8.00	15.13%	GWAPD	10
Cefuroxime*	Tablet 250 mg (as axetil)	Oral	9.38	15.13	7.96	9.38	15.14%	GWAPD	10
Entecavir	Tablet 0.5 mg (as monohydrate)	Oral	121.25	49.05	61.78	72.51	14.80%	GWAPD	10
Entecavir	Tablet 1 mg (as monohydrate)	Oral	197.18	49.05	100.46	117.91	14.80%	GWAPD	10
Ezetimibe	Tablet 10 mg	Oral	17.56	38.33	10.83	12.71	14.79%	Does not meet 30 month clock	10
Filgrastim*	Injection 300 micrograms in 0.5 mL single-use pre-filled syringe	Injection	154.80	44.27	86.27	154.80	44.27%	GWAPD	30
Filgrastim*	Injection 480 micrograms in 0.5 mL single-use pre-filled syringe	Injection	248.15	44.27	138.29	248.15	44.27%	GWAPD	30
Filgrastim*	Injection 480 micrograms in 1.6 mL	Injection	496.31	44.27	276.59	496.31	44.27%	GWAPD	30
Ganciclovir	Powder for I.V. infusion 500 mg (as sodium)	Injection	158.37	16.53	132.19	158.37	16.53%	Does not meet 30 month clock	10
Ibuprofen	Tablet 400 mg	Oral	1.79	16.20	1.50	1.79	16.20%	GWAPD	10
Moxonidine	Tablet 200 micrograms	Oral	7.10	10.39	6.36	7.10	10.42%	Does not meet 30 month clock	10
Moxonidine	Tablet 400 micrograms	Oral	12.10	10.39	10.84	12.10	10.41%	Does not meet 30 month clock	10
Naloxone	Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe	Injection	27.77	19.74	22.29	27.77	19.73%	OWAPD	10
Naloxone	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	Injection	31.49	19.74	25.27	31.49	19.75%	OWAPD	10
Nortriptyline	Tablet 10 mg (as hydrochloride)	Oral	4.45	20.22	3.55	4.45	20.22%	GWAPD	10
Nortriptyline	Tablet 25 mg (as hydrochloride)	Oral	5.60	20.36	4.46	5.60	20.36%	GWAPD	10
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	4.66	11.70	4.11	4.66	11.80%	OWAPD	10
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	9.60	11.70	8.48	9.60	11.67%	OWAPD	10
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	8.96	11.70	7.91	8.96	11.72%	OWAPD	10
Pegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection	1175.00	70.52	346.39	934.95	62.95%	GWAPD	10
Pregabalin	Capsule 150 mg	Oral	24.02	39.77	14.47	18.42	21.44%	GWAPD	10
Pregabalin	Capsule 25 mg	Oral	7.08	39.77	4.26	5.43	21.55%	GWAPD	10
Pregabalin	Capsule 300 mg	Oral	35.84	39.77	21.59	27.48	21.43%	GWAPD	10
Pregabalin	Capsule 75 mg	Oral	15.66	39.77	9.43	12.01	21.48%	GWAPD	10
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	Oral	27.35	30.10	19.12	27.35	30.09%	GWAPD	30
Rituximab	Solution for I.V. infusion 100 mg in 10 mL	Injection	479.73	35.27	310.53	388.87	20.15%	Does not meet 30 month clock	10
Rituximab	Solution for I.V. infusion 500 mg in 50 mL	Injection	1199.32	35.27	776.32	972.17	20.15%	Does not meet 30 month clock	10
Rituximab	Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL	Injection	1699.12	35.27	1099.84	1699.12	35.27%	Does not meet 30 month clock	10
Rosuvastatin*	Tablet 20 mg (as calcium)	Oral	5.11	30.62	3.55	5.11	30.53%	GWAPD	30
Rosuvastatin*	Tablet 40 mg (as calcium)	Oral	7.30	30.62	5.06	7.30	30.68%	GWAPD	30
Rosuvastatin*	Tablet 5 mg (as calcium)	Oral	2.45	30.62	1.70	2.45	30.61%	GWAPD	30
Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	198.79	10.84	177.24	198.79	10.84%	Does not meet 30 month clock	10
Sevelamer	Tablet containing sevelamer hydrochloride 800 mg	Oral	198.79	10.84	177.24	198.79	10.84%	Does not meet 30 month clock	10
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	339.37	41.95	197.00	298.88	34.09%	GWAPD	10
Tenofovir	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	339.37	41.95	197.00	298.88	34.09%	GWAPD	10
Tenofovir	Tablet containing tenofovir disoproxil phosphate 291 mg	Oral	339.37	41.95	197.00	298.88	34.09%	GWAPD	10
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	92.49	41.82	53.81	92.49	41.82%	OWAPD	10
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	Oral	92.49	41.82	53.81	92.49	41.82%	OWAPD	10
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg	Oral	92.49	41.82	53.81	92.49	41.82%	OWAPD	10
Tranexamic acid	Tablet 500 mg	Oral	27.14	12.16	23.84	27.14	12.16%	GWAPD	10
Trastuzumab*	Powder for I.V. infusion 150 mg	Injection	533.22	20.17	375.39	470.25	20.17%	Does not meet 30 month clock	10
Trastuzumab*	Powder for I.V. infusion 420 mg	Injection	1493.02	20.17	1057.09	1316.69	20.17%	Does not meet 30 month clock	10
Trastuzumab*	Powder for I.V. infusion 60 mg	Injection	213.29	20.17	150.16	188.10	20.17%	Does not meet 30 month clock	10
Valganciclovir	Tablet 450 mg (as hydrochloride)	Oral	713.52	23.23	547.77	713.52	23.23%	GWAPD	10

Price Disclosure Reductions for 2021 April Cycle

Flow-on Reductions for F2 Combination Items

Legal Determination & Next Steps

Department of Health and Aged Care

Pharmaceutical Benefits Scheme

PBS Information

Browse the PBS

For Health Professionals

For Industry